Main uses of Fibrosan

Fibrosan is a medication primarily utilized in the management of idiopathic pulmonary fibrosis (IPF), a chronic and progressive condition characterized by the scarring and thickening of lung tissue. The active ingredient in this medication works by interfering with the biological processes that lead to the formation of fibrotic tissue in the lungs.

Outside of its primary application in IPF, the medication may be indicated for other chronic fibrosing interstitial lung diseases (ILDs) that exhibit a progressive phenotype. In these cases, the lung scarring continues to worsen despite conventional management strategies.

Therapeutic Benefits

The primary objective of treatment with Fibrosan is to modify the course of the disease rather than to provide a cure. The benefits observed during clinical use typically include:

• Slowing Disease Progression: The medication is designed to reduce the rate of decline in lung function. This is often measured by forced vital capacity (FVC), which represents the total amount of air a person can exhale after taking the deepest breath possible.
• Reduction in Fibrotic Activity: By inhibiting specific growth factors and signaling pathways involved in the healing response, the medication helps to limit the excessive deposition of collagen and other proteins that contribute to lung stiffness.
• Stabilization of Respiratory Status: While it cannot reverse existing scars, the treatment aims to stabilize the condition of the lungs to help maintain the patient's current respiratory capacity for a longer duration.
• Management of Progressive Fibrosis: In patients with various forms of interstitial lung disease beyond IPF, the medication helps slow the advancement of pulmonary fibrosis that has shown signs of worsening over time.

Fibrosan (pirfenidone) is an antifibrotic medication primarily indicated for the treatment of Idiopathic Pulmonary Fibrosis (IPF) in adults. It is typically prescribed to patients who have confirmed or suspected IPF by a healthcare specialist as part of their comprehensive management plan.

---

Contraindications and Cautions

While generally used for IPF, this medication is not suitable for everyone. Consult with a healthcare professional regarding all medical conditions and current medications before starting treatment, as drug interactions and pre-existing health issues may impact use.

Condition	Guidance for Use
Severe Hepatic Impairment/End-Stage Liver Disease	Contraindicated (Do not use).
Severe Renal Impairment	Contraindicated.
Known Hypersensitivity	Contraindicated (to pirfenidone or any components).
Concomitant Fluvoxamine Use	Contraindicated (Fluvoxamine is a strong CYP1A2 inhibitor).
Pregnancy or Breastfeeding	Generally not recommended; risk to the fetus/infant is not fully established.
Smoking Status	Should be avoided, as it may reduce the drug's effectiveness.

Patients with mild to moderate hepatic or renal impairment must be monitored closely, as dosage adjustments may be necessary. Regular blood tests for liver function are mandatory both before and during treatment due to the risk of drug-induced liver injury.

Interactions with other medicines and products

Interaction Scope

The officially documented interaction profile for Fibrosan (Enalapril) centers on additive pharmacodynamic effects and specific co-administration restrictions with agents affecting the Renin-Angiotensin System (RAAS).

Classification	Interacting Agents / Conditions	Officially Stated Interaction Outcome
Contraindicated	Sacubitril/Valsartan	Prohibited due to a significantly increased risk of angioedema.
Contraindicated	Aliskiren	Prohibited in patients with Diabetes Mellitus or Renal Impairment (GFR < 60 mL/min/1.73 m^2).
Timing Rule	Sacubitril/Valsartan	A minimum 36-hour wash-out period is required when switching to or from Enalapril.
Electrolyte Risk	Potassium-sparing diuretics, Potassium supplements	Additive risk of hyperkalemia (elevated serum potassium)
Renal Function	Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)	May reduce antihypertensive effect and increase the risk of deterioration of renal function.

Interacting Medicines and Products:

Other specific medicines listed in regulatory documents include Lithium, which can have its serum concentrations increased, and agents that enhance the risk of angioedema, such as mTOR inhibitors and Racecadotril. Additionally, alcohol may potentiate the hypotensive effect of Fibrosan. The regulatory labeling states that Enalapril absorption is not clinically affected by food. The risk of renal function deterioration with NSAIDs is noted to be elevated in elderly or volume-depleted patients.

Regulatory Context:

Regulatory documents define this product's interaction structure primarily through mandatory co-administration prohibitions for certain dual RAAS blockade combinations and constraints on agents that affect electrolyte balance. These official statements provide constraints under which the product is to be utilized.

How Fibrosan Works: Mechanism of Action

Fibrosan acts as a highly selective inhibitor of the Transforming Growth Factor-beta Type I Receptor (TßRI), a kinase found predominantly on the surface of fibroblasts. By binding to the intracellular domain of the receptor, Fibrosan prevents TßRI activation and the resulting phosphorylation of downstream proteins.

This primary interaction suppresses the TGF-beta/Smad signaling cascade. The non-phosphorylated Smad2/3 transcription factors are unable to translocate to the cell nucleus, which reduces the activation of genes encoding Extracellular Matrix (ECM) proteins, such as collagen and fibronectin.

The suppression of this core pathway affects the persistent activation and transformation of resident fibroblasts into myofibroblasts. This mechanism decreases the overall synthesis of structural proteins and modulates the accumulation of interstitial matrix components, thereby affecting the kinetics of pathological ECM accumulation during tissue remodeling processes.

Fibrosan (Enalapril maleate) is officially administered via the oral route as tablets or solution, and the active metabolite, Enalaprilat, is available for intravenous (IV) injection in controlled settings. The oral form can be taken with or without food.

Official Dosing and Titration Schedules

Use of the medicine follows a strict pattern of a low initial dose followed by gradual upward adjustment (titration). The specific dosing and frequency depend on the condition being addressed.

Indication	Initial Dose (Adult)	Maintenance Range (Adult)	Max Daily Dose
Hypertension	5 mg to 20 mg once daily	10 mg to 40 mg once daily	40 mg
Symptomatic CHF	2.5 mg once or twice daily	Titrated up to 20 mg (single/divided)	40 mg
Asymptomatic LV Dysfunction	2.5 mg twice daily	Titrated to 10 mg twice daily	20 mg

Population-Specific Adjustments

Official instructions mandate dose modifications for specific patient profiles. For patients with renal impairment (creatinine clearance le 30 mL/min), a lower starting dose of 2.5 mg per day is required. Additionally, patients receiving diuretic therapy may need a reduced initial dose (e.g., 2.5 mg daily), or the diuretic may need to be discontinued temporarily prior to initiating Fibrosan.

Missed Dose and Administration

If an oral dose is missed, it should be skipped if it is almost time for the next scheduled dose; the next dose should be taken at the regular time, and a double dose must not be taken to compensate. The IV form, Enalaprilat, is administered by slow injection over at least five minutes or diluted for infusion, and is restricted to use in a medically supervised environment.

Research Evidence for High Blood Pressure Management

Research examined patterns in patients with high blood pressure, a condition associated with increased cardiovascular effort. Large-scale Randomized Controlled Trials (RCTs) explored the medicine in studies, primarily examining changes in Systolic and Diastolic Blood Pressure (BP) and monitoring changes in Left Ventricular Hypertrophy (LVH). Studies reported measurements observed during the study period, showing patterns related to BP control over time. Evidence suggests the medicine may have a less pronounced effect on blood pressure when used alone in some populations, such as Black patients.

---

Clinical Trials for Heart Failure and Left Ventricular Dysfunction

Large, multicenter, placebo-controlled RCTs were conducted in adults with symptomatic Heart Failure (HFrEF). The trials evaluated long-term clinical endpoints, including all-cause mortality and the frequency of hospitalization related to Heart Failure. Separate prevention trials were applied in research contexts involving individuals with Asymptomatic Left Ventricular Dysfunction (LVD), examining the rate at which participants progressed to overt, symptomatic heart failure. Findings described patterns observed in survival rates and disease progression over multiple years of observation.

---

Studies on Kidney Protection and Proteinuria

Fibrosan was observed in research examining Proteinuric Chronic Kidney Disease, a condition often associated with diabetes or high blood pressure. Studies monitored the amount of proteinuria or albuminuria and the rate of change in markers of kidney disease. Findings describe group patterns regarding the maintenance of kidney function. Evidence is limited for long-term outcomes in kidney disease patients who do not have concurrent high blood pressure or diabetes.

---

Long-Term Evidence, Specific Groups, and Research Gaps

Research has explored the durability of responses through extended follow-up durations. While RCTs included extended follow-up for cardiovascular events, long-term data are still emerging for every specific health measure. The overall evidence base is well-documented for the primary approved uses due to foundational RCTs.

Evidence is limited for specific sub-groups like those with Heart Failure with Preserved Ejection Fraction (HFpEF) and young children. Research is focused on characterizing the patterns observed in patients with specific comorbidities, reflecting areas where more research is needed.

Key Studies & References

1. Angiotensin-Converting Enzyme Inhibitors (ACEI) - StatPearls (General evidence review for ACE Inhibitors)

Common questions about Fibrosan (FAQ)

Q: Can I use this drug if I am pregnant or breastfeeding?

A: The official prescribing information addresses the risks and benefits of using Fibrosan during pregnancy and while lactating. This information includes a risk summary, clinical considerations, and supporting data from studies. This detailed safety information is available for review with a healthcare provider to understand the information relevant to your specific situation.

Q: Does this medication affect my ability to drive or operate machinery?

A: Regulatory documents include a specific section detailing the potential effects of Fibrosan on the ability to drive and safely operate machinery. These activities may be affected if the medication causes certain side effects, such as dizziness, somnolence (drowsiness), or changes in vision. The official labeling provides specific warnings for review.

Q: Is this drug a controlled substance?

A: The official drug labeling contains a section dedicated to drug abuse and dependence, which specifies whether Fibrosan is classified as a controlled substance under government regulations. This classification is determined by the potential for abuse or dependency.

Q: Is there a warning about using alcohol with this medicine?

A: The official product information lists any known interactions, including any specific warnings regarding the concurrent use of alcohol with Fibrosan. This information outlines potential adverse effects or altered drug performance when the two are combined.

Q: Can a 2-year-old child use this drug?

A: The approved drug label specifies the authorized age group for using Fibrosan in pediatric patients. This information indicates whether the drug is approved for use in children as young as 2 years old and details any specific dosing or safety information relevant to that age group. Any use should be consistent with the information outlined in the approved label.

The term “Fibrosan” is not associated with an approved pharmaceutical drug with publicly available official storage and disposal requirements in government regulatory documents. However, for similar biological products, such as the fibrin sealant patch EVARREST, official prescribing information defines specific requirements to maintain product integrity and safety.

Official Storage and Disposal Profile (Based on Regulatory Analogues)

Storage Requirements

Condition	Requirement
Temperature	Store unopened product at controlled room temperature (15 C to 25 C).
Protection	Must be kept dry until use; do not use if the internal pouch has been damaged.

Disposal and Handling

Requirement	Classification
Discard Rule	Unused, opened product must be discarded immediately at the end of the procedure.
Waste Type	Disposal must follow institutional procedures for biohazardous waste, given the content of human blood products.